Dear Colleagues – We wanted to let you know about an important development at the Drug Enforcement Administration regarding its notice of intent to place mitragynine and 7-hydroxymitragynine, two substances of the plant Mitragyna speciosa also referred to as kratom, in Schedule I. According to our colleagues at the DEA, since publishing that notice, they have received a number of comments from members of the public. Some of the commenters offered their opinions regarding the pharmacological effects of mitragynine and 7-hydroxymitragynine. To allow consideration of these comments, as well as others, DEA has withdrawn its notice of intent to temporarily place Schedule I controls on kratom and is soliciting public comments until December 1, 2016.
DEA’s withdrawal notice and solicitation of comments may be found here: https://www.federalregister.gov/documents/2016/10/13/2016-24659/schedules-of-controlled-substances-temporary-placement-of-mitragynine-and-7-hydroxymitragynine-into
Should you have any questions, please contact the DEA’s Office of Congressional and Public Affairs at 202-307-7423.
Senior Advisor to the Director
Office of Science Policy and Communications
National Institute on Drug Abuse
6001 Executive Blvd.
Bethesda, MD 20892
PLEASE NOTE NEW PHONE: 301.480.2850
Science = Solutions
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to firstname.lastname@example.org Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L in the message body of the email - You will receive a confirmation email if successful. If you have problems contact email@example.com 301-435-1309